-
1 Comment
Groupe Actiplay SA is currently in a long term uptrend where the price is trading 113.6% above its 200 day moving average.
From a valuation standpoint, the stock is 66.1% cheaper than other stocks from the Communication Services sector with a price to sales ratio of 2.0.
Based on the above factors, Groupe Actiplay SA gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | FR0014005OJ5 |
| CurrencyCode | EUR |
| Exchange | PA |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 9.5 |
| Beta | 2.44 |
| PE Ratio | None |
| Market Cap | 76M |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALACT.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
